ORIC Pharmaceuticals

South San Fransisco, CA

Job posting number: #7078660 (Ref:410-2020)

Posted: May 18, 2021

Application Deadline: Open Until Filled

Job Description

We are seeking a highly motivated Scientist, DMPK to characterize the in vitro and in vivo ADME properties of drug candidates. They will work in ORIC drug discovery and development project teams with the goal of developing therapeutics to overcome resistance in cancer. The primary responsibilities will be to conduct in vitro experiments and conduct bioanalysis for in vivo samples. They are expected to independently plan and execute experiments, interpret results and troubleshoot problems.

Essential duties and responsibilities include, but are not limited to, the following tasks:

• Provide bioanalytical support for in-house PK, non-GLP toxicology and in vitro and in vivo PK-PD/efficacy studies.
• Independently design, conduct, analyze and interpret in vitro ADME experiments including in vitro stability (e.g. microsomal, hepatocyte and plasma) and protein binding.
• Provide formulation support for in-house in vivo studies.
• Independently develop LC-MS/MS methods to quantitate small molecules in in vitro and in vivo samples.
• Independently operate, troubleshoot and maintain LC-MS/MS and analytical equipment.
• Participate in multidisciplinary project teams and collaborate with other departments, including pharmacology, chemistry and biology.
• Maintain accurate and detailed scientific notebooks.
• Ability to think and plan strategically, and excellent interpersonal skills and ability to work in a team environment.
• Perform all duties in keeping with the Company's core values, policies and all applicable regulations.
• Assist in the preparation of DMPK components of nonclinical and clinical study protocol designs, nonclinical and clinical study reports, and investigator brochures.
• Participate in the preparation of abstracts and manuscripts for publication.
• Perform all duties in keeping with the Company's core values, policies and all applicable regulations.

Education and Requirements:
• PhD with 0-2 years or Masters Degree with 7+ years or Bachelor Degree with 1 0+ years of professional experience in an industry setting.
• Experience with H/UPLC and mass spectrometry is a must.
• PK analysis using Phoenix or other data management software is a must.
• Manage collaborations with CROs for outsourcing activities is preferred.
• Provide sample analysis to support PK, PK/PD, PK/efficacy, distribution, metabolism, and non-GLP toxicology studies
• Independently plans and executes in vitro ADME assays. Identifies and applies new experimental methods and techniques . Be able to troubleshoot and identify solutions to arising issues.
• Decides upon (experimental) strategy to answer specific scientific questions. Interprets results and presents to manager and team members.
• Identify issues and troubleshoot scientific equipment including LC-MS/MS, select and develop appropriate methods to perform experiments, analyze data and prepare related reports.
• Excellent oral and written communication skills.
• Maintain detailed up to date raw data and lab notebooks with all relevant documentation and electronic files. Contribute to and support regulatory filing or publications by providing experimental procedure and data and preparing figures.

About ORIC Pharmaceuticals
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi (enzalutamide) in metastatic prostate cancer and (2) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, and (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to

Apply Now

Please mention to the employer that you saw this ad on